http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 28 Jul 2025 08:00:30 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Board+Changes/Lantern+Pharma+appoints+Dr.+Lee+Schalop+to+board+of+directors/25103060.html <p>Lantern Pharma Inc. (NASDAQ: LTRN) announced the appointment of Dr. Lee T. Schalop to its board of directors, according to a company press release.</p> <p>Dr. Schalop brings more than 20 years of experience in biotechnology leadership and financial markets, with expertise in precision neurooncology and clinical development. He co-founded Oncoceutics Inc., a drug discovery company focused on targeted therapies for solid tumors, which was sold to Chimerix Inc. for $450 million in January 2021.</p> <p>At Oncoceutics, Dr. Schalop served in various roles including Chief Business Officer from 2009-2016, Chief Operating Officer from 2016-2020, and Chief Executive Officer from 2020-2021. Following the Chimerix http://www.streetinsider.com/Board+Changes/Lantern+Pharma+appoints+Dr.+Lee+Schalop+to+board+of+directors/25103060.html Mon, 28 Jul 2025 08:00:30 -0400 0N6A A.00756693 A.03607790 A.13384720 A.16949560 A.35871300 ALTME CMRX LTRN O.00159267 O.20147506 O.20831026 O.30873959 O.40825805 O.47731837 http://www.streetinsider.com/Board+Changes/Lantern+Pharma+appoints+Dr.+Lee+Schalop+to+board+of+directors/25103060.html <p>Lantern Pharma Inc. (NASDAQ: LTRN) announced the appointment of Dr. Lee T. Schalop to its board of directors, according to a company press release.</p> <p>Dr. Schalop brings more than 20 years of experience in biotechnology leadership and financial markets, with expertise in precision neurooncology and clinical development. He co-founded Oncoceutics Inc., a drug discovery company focused on targeted therapies for solid tumors, which was sold to Chimerix Inc. for $450 million in January 2021.</p> <p>At Oncoceutics, Dr. Schalop served in various roles including Chief Business Officer from 2009-2016, Chief Operating Officer from 2016-2020, and Chief Executive Officer from 2020-2021. Following the Chimerix http://www.streetinsider.com/Board+Changes/Lantern+Pharma+appoints+Dr.+Lee+Schalop+to+board+of+directors/25103060.html Mon, 28 Jul 2025 08:00:30 -0400 0N6A A.00756693 A.03607790 A.13384720 A.16949560 A.35871300 ALTME CMRX LTRN O.00159267 O.20147506 O.20831026 O.30873959 O.40825805 O.47731837 http://www.streetinsider.com/Board+Changes/Lantern+Pharma+appoints+Dr.+Lee+Schalop+to+board+of+directors/25103060.html <p>Lantern Pharma Inc. (NASDAQ: LTRN) announced the appointment of Dr. Lee T. Schalop to its board of directors, according to a company press release.</p> <p>Dr. Schalop brings more than 20 years of experience in biotechnology leadership and financial markets, with expertise in precision neurooncology and clinical development. He co-founded Oncoceutics Inc., a drug discovery company focused on targeted therapies for solid tumors, which was sold to Chimerix Inc. for $450 million in January 2021.</p> <p>At Oncoceutics, Dr. Schalop served in various roles including Chief Business Officer from 2009-2016, Chief Operating Officer from 2016-2020, and Chief Executive Officer from 2020-2021. Following the Chimerix http://www.streetinsider.com/Board+Changes/Lantern+Pharma+appoints+Dr.+Lee+Schalop+to+board+of+directors/25103060.html Mon, 28 Jul 2025 08:00:30 -0400 0N6A A.00756693 A.03607790 A.13384720 A.16949560 A.35871300 ALTME CMRX LTRN O.00159267 O.20147506 O.20831026 O.30873959 O.40825805 O.47731837 http://www.streetinsider.com/Board+Changes/Lantern+Pharma+appoints+Dr.+Lee+Schalop+to+board+of+directors/25103060.html <p>Lantern Pharma Inc. (NASDAQ: LTRN) announced the appointment of Dr. Lee T. Schalop to its board of directors, according to a company press release.</p> <p>Dr. Schalop brings more than 20 years of experience in biotechnology leadership and financial markets, with expertise in precision neurooncology and clinical development. He co-founded Oncoceutics Inc., a drug discovery company focused on targeted therapies for solid tumors, which was sold to Chimerix Inc. for $450 million in January 2021.</p> <p>At Oncoceutics, Dr. Schalop served in various roles including Chief Business Officer from 2009-2016, Chief Operating Officer from 2016-2020, and Chief Executive Officer from 2020-2021. Following the Chimerix http://www.streetinsider.com/Board+Changes/Lantern+Pharma+appoints+Dr.+Lee+Schalop+to+board+of+directors/25103060.html Mon, 28 Jul 2025 08:00:30 -0400 0N6A A.00756693 A.03607790 A.13384720 A.16949560 A.35871300 ALTME CMRX LTRN O.00159267 O.20147506 O.20831026 O.30873959 O.40825805 O.47731837 http://www.streetinsider.com/Board+Changes/Lantern+Pharma+appoints+Dr.+Lee+Schalop+to+board+of+directors/25103060.html <p>Lantern Pharma Inc. (NASDAQ: LTRN) announced the appointment of Dr. Lee T. Schalop to its board of directors, according to a company press release.</p> <p>Dr. Schalop brings more than 20 years of experience in biotechnology leadership and financial markets, with expertise in precision neurooncology and clinical development. He co-founded Oncoceutics Inc., a drug discovery company focused on targeted therapies for solid tumors, which was sold to Chimerix Inc. for $450 million in January 2021.</p> <p>At Oncoceutics, Dr. Schalop served in various roles including Chief Business Officer from 2009-2016, Chief Operating Officer from 2016-2020, and Chief Executive Officer from 2020-2021. Following the Chimerix http://www.streetinsider.com/Board+Changes/Lantern+Pharma+appoints+Dr.+Lee+Schalop+to+board+of+directors/25103060.html Mon, 28 Jul 2025 08:00:30 -0400 0N6A A.00756693 A.03607790 A.13384720 A.16949560 A.35871300 ALTME CMRX LTRN O.00159267 O.20147506 O.20831026 O.30873959 O.40825805 O.47731837 http://www.streetinsider.com/Board+Changes/Lantern+Pharma+appoints+Dr.+Lee+Schalop+to+board+of+directors/25103060.html <p>Lantern Pharma Inc. (NASDAQ: LTRN) announced the appointment of Dr. Lee T. Schalop to its board of directors, according to a company press release.</p> <p>Dr. Schalop brings more than 20 years of experience in biotechnology leadership and financial markets, with expertise in precision neurooncology and clinical development. He co-founded Oncoceutics Inc., a drug discovery company focused on targeted therapies for solid tumors, which was sold to Chimerix Inc. for $450 million in January 2021.</p> <p>At Oncoceutics, Dr. Schalop served in various roles including Chief Business Officer from 2009-2016, Chief Operating Officer from 2016-2020, and Chief Executive Officer from 2020-2021. Following the Chimerix http://www.streetinsider.com/Board+Changes/Lantern+Pharma+appoints+Dr.+Lee+Schalop+to+board+of+directors/25103060.html Mon, 28 Jul 2025 08:00:30 -0400 0N6A A.00756693 A.03607790 A.13384720 A.16949560 A.35871300 ALTME CMRX LTRN O.00159267 O.20147506 O.20831026 O.30873959 O.40825805 O.47731837 http://www.streetinsider.com/Board+Changes/Lantern+Pharma+appoints+Dr.+Lee+Schalop+to+board+of+directors/25103060.html <p>Lantern Pharma Inc. (NASDAQ: LTRN) announced the appointment of Dr. Lee T. Schalop to its board of directors, according to a company press release.</p> <p>Dr. Schalop brings more than 20 years of experience in biotechnology leadership and financial markets, with expertise in precision neurooncology and clinical development. He co-founded Oncoceutics Inc., a drug discovery company focused on targeted therapies for solid tumors, which was sold to Chimerix Inc. for $450 million in January 2021.</p> <p>At Oncoceutics, Dr. Schalop served in various roles including Chief Business Officer from 2009-2016, Chief Operating Officer from 2016-2020, and Chief Executive Officer from 2020-2021. Following the Chimerix http://www.streetinsider.com/Board+Changes/Lantern+Pharma+appoints+Dr.+Lee+Schalop+to+board+of+directors/25103060.html Mon, 28 Jul 2025 08:00:30 -0400 0N6A A.00756693 A.03607790 A.13384720 A.16949560 A.35871300 ALTME CMRX LTRN O.00159267 O.20147506 O.20831026 O.30873959 O.40825805 O.47731837 http://www.streetinsider.com/Board+Changes/Lantern+Pharma+appoints+Dr.+Lee+Schalop+to+board+of+directors/25103060.html <p>Lantern Pharma Inc. (NASDAQ: LTRN) announced the appointment of Dr. Lee T. Schalop to its board of directors, according to a company press release.</p> <p>Dr. Schalop brings more than 20 years of experience in biotechnology leadership and financial markets, with expertise in precision neurooncology and clinical development. He co-founded Oncoceutics Inc., a drug discovery company focused on targeted therapies for solid tumors, which was sold to Chimerix Inc. for $450 million in January 2021.</p> <p>At Oncoceutics, Dr. Schalop served in various roles including Chief Business Officer from 2009-2016, Chief Operating Officer from 2016-2020, and Chief Executive Officer from 2020-2021. Following the Chimerix http://www.streetinsider.com/Board+Changes/Lantern+Pharma+appoints+Dr.+Lee+Schalop+to+board+of+directors/25103060.html Mon, 28 Jul 2025 08:00:30 -0400 0N6A A.00756693 A.03607790 A.13384720 A.16949560 A.35871300 ALTME CMRX LTRN O.00159267 O.20147506 O.20831026 O.30873959 O.40825805 O.47731837 http://www.streetinsider.com/Board+Changes/Lantern+Pharma+appoints+Dr.+Lee+Schalop+to+board+of+directors/25103060.html <p>Lantern Pharma Inc. (NASDAQ: LTRN) announced the appointment of Dr. Lee T. Schalop to its board of directors, according to a company press release.</p> <p>Dr. Schalop brings more than 20 years of experience in biotechnology leadership and financial markets, with expertise in precision neurooncology and clinical development. He co-founded Oncoceutics Inc., a drug discovery company focused on targeted therapies for solid tumors, which was sold to Chimerix Inc. for $450 million in January 2021.</p> <p>At Oncoceutics, Dr. Schalop served in various roles including Chief Business Officer from 2009-2016, Chief Operating Officer from 2016-2020, and Chief Executive Officer from 2020-2021. Following the Chimerix http://www.streetinsider.com/Board+Changes/Lantern+Pharma+appoints+Dr.+Lee+Schalop+to+board+of+directors/25103060.html Mon, 28 Jul 2025 08:00:30 -0400 0N6A A.00756693 A.03607790 A.13384720 A.16949560 A.35871300 ALTME CMRX LTRN O.00159267 O.20147506 O.20831026 O.30873959 O.40825805 O.47731837 http://www.streetinsider.com/Board+Changes/Lantern+Pharma+appoints+Dr.+Lee+Schalop+to+board+of+directors/25103060.html <p>Lantern Pharma Inc. (NASDAQ: LTRN) announced the appointment of Dr. Lee T. Schalop to its board of directors, according to a company press release.</p> <p>Dr. Schalop brings more than 20 years of experience in biotechnology leadership and financial markets, with expertise in precision neurooncology and clinical development. He co-founded Oncoceutics Inc., a drug discovery company focused on targeted therapies for solid tumors, which was sold to Chimerix Inc. for $450 million in January 2021.</p> <p>At Oncoceutics, Dr. Schalop served in various roles including Chief Business Officer from 2009-2016, Chief Operating Officer from 2016-2020, and Chief Executive Officer from 2020-2021. Following the Chimerix http://www.streetinsider.com/Board+Changes/Lantern+Pharma+appoints+Dr.+Lee+Schalop+to+board+of+directors/25103060.html Mon, 28 Jul 2025 08:00:30 -0400 0N6A A.00756693 A.03607790 A.13384720 A.16949560 A.35871300 ALTME CMRX LTRN O.00159267 O.20147506 O.20831026 O.30873959 O.40825805 O.47731837 http://www.streetinsider.com/Board+Changes/Lantern+Pharma+appoints+Dr.+Lee+Schalop+to+board+of+directors/25103060.html <p>Lantern Pharma Inc. (NASDAQ: LTRN) announced the appointment of Dr. Lee T. Schalop to its board of directors, according to a company press release.</p> <p>Dr. Schalop brings more than 20 years of experience in biotechnology leadership and financial markets, with expertise in precision neurooncology and clinical development. He co-founded Oncoceutics Inc., a drug discovery company focused on targeted therapies for solid tumors, which was sold to Chimerix Inc. for $450 million in January 2021.</p> <p>At Oncoceutics, Dr. Schalop served in various roles including Chief Business Officer from 2009-2016, Chief Operating Officer from 2016-2020, and Chief Executive Officer from 2020-2021. Following the Chimerix http://www.streetinsider.com/Board+Changes/Lantern+Pharma+appoints+Dr.+Lee+Schalop+to+board+of+directors/25103060.html Mon, 28 Jul 2025 08:00:30 -0400 0N6A A.00756693 A.03607790 A.13384720 A.16949560 A.35871300 ALTME CMRX LTRN O.00159267 O.20147506 O.20831026 O.30873959 O.40825805 O.47731837 http://www.streetinsider.com/Board+Changes/Lantern+Pharma+appoints+Dr.+Lee+Schalop+to+board+of+directors/25103060.html <p>Lantern Pharma Inc. (NASDAQ: LTRN) announced the appointment of Dr. Lee T. Schalop to its board of directors, according to a company press release.</p> <p>Dr. Schalop brings more than 20 years of experience in biotechnology leadership and financial markets, with expertise in precision neurooncology and clinical development. He co-founded Oncoceutics Inc., a drug discovery company focused on targeted therapies for solid tumors, which was sold to Chimerix Inc. for $450 million in January 2021.</p> <p>At Oncoceutics, Dr. Schalop served in various roles including Chief Business Officer from 2009-2016, Chief Operating Officer from 2016-2020, and Chief Executive Officer from 2020-2021. Following the Chimerix http://www.streetinsider.com/Board+Changes/Lantern+Pharma+appoints+Dr.+Lee+Schalop+to+board+of+directors/25103060.html Mon, 28 Jul 2025 08:00:30 -0400 0N6A A.00756693 A.03607790 A.13384720 A.16949560 A.35871300 ALTME CMRX LTRN O.00159267 O.20147506 O.20831026 O.30873959 O.40825805 O.47731837 http://www.streetinsider.com/Board+Changes/Lantern+Pharma+appoints+Dr.+Lee+Schalop+to+board+of+directors/25103060.html <p>Lantern Pharma Inc. (NASDAQ: LTRN) announced the appointment of Dr. Lee T. Schalop to its board of directors, according to a company press release.</p> <p>Dr. Schalop brings more than 20 years of experience in biotechnology leadership and financial markets, with expertise in precision neurooncology and clinical development. He co-founded Oncoceutics Inc., a drug discovery company focused on targeted therapies for solid tumors, which was sold to Chimerix Inc. for $450 million in January 2021.</p> <p>At Oncoceutics, Dr. Schalop served in various roles including Chief Business Officer from 2009-2016, Chief Operating Officer from 2016-2020, and Chief Executive Officer from 2020-2021. Following the Chimerix http://www.streetinsider.com/Board+Changes/Lantern+Pharma+appoints+Dr.+Lee+Schalop+to+board+of+directors/25103060.html Mon, 28 Jul 2025 08:00:30 -0400 0N6A A.00756693 A.03607790 A.13384720 A.16949560 A.35871300 ALTME CMRX LTRN O.00159267 O.20147506 O.20831026 O.30873959 O.40825805 O.47731837 http://www.streetinsider.com/Board+Changes/Lantern+Pharma+appoints+Dr.+Lee+Schalop+to+board+of+directors/25103060.html <p>Lantern Pharma Inc. (NASDAQ: LTRN) announced the appointment of Dr. Lee T. Schalop to its board of directors, according to a company press release.</p> <p>Dr. Schalop brings more than 20 years of experience in biotechnology leadership and financial markets, with expertise in precision neurooncology and clinical development. He co-founded Oncoceutics Inc., a drug discovery company focused on targeted therapies for solid tumors, which was sold to Chimerix Inc. for $450 million in January 2021.</p> <p>At Oncoceutics, Dr. Schalop served in various roles including Chief Business Officer from 2009-2016, Chief Operating Officer from 2016-2020, and Chief Executive Officer from 2020-2021. Following the Chimerix http://www.streetinsider.com/Board+Changes/Lantern+Pharma+appoints+Dr.+Lee+Schalop+to+board+of+directors/25103060.html Mon, 28 Jul 2025 08:00:30 -0400 0N6A A.00756693 A.03607790 A.13384720 A.16949560 A.35871300 ALTME CMRX LTRN O.00159267 O.20147506 O.20831026 O.30873959 O.40825805 O.47731837 http://www.streetinsider.com/Board+Changes/Lantern+Pharma+appoints+Dr.+Lee+Schalop+to+board+of+directors/25103060.html <p>Lantern Pharma Inc. (NASDAQ: LTRN) announced the appointment of Dr. Lee T. Schalop to its board of directors, according to a company press release.</p> <p>Dr. Schalop brings more than 20 years of experience in biotechnology leadership and financial markets, with expertise in precision neurooncology and clinical development. He co-founded Oncoceutics Inc., a drug discovery company focused on targeted therapies for solid tumors, which was sold to Chimerix Inc. for $450 million in January 2021.</p> <p>At Oncoceutics, Dr. Schalop served in various roles including Chief Business Officer from 2009-2016, Chief Operating Officer from 2016-2020, and Chief Executive Officer from 2020-2021. Following the Chimerix http://www.streetinsider.com/Board+Changes/Lantern+Pharma+appoints+Dr.+Lee+Schalop+to+board+of+directors/25103060.html Mon, 28 Jul 2025 08:00:30 -0400 0N6A A.00756693 A.03607790 A.13384720 A.16949560 A.35871300 ALTME CMRX LTRN O.00159267 O.20147506 O.20831026 O.30873959 O.40825805 O.47731837 http://www.streetinsider.com/Press+Releases/Lantern+Pharma+Announces+Appointment+of+Dr.+Lee+Schalop+to+Board+of+Directors/25103014.html <ul class="bwlistsquare"> <li> Seasoned Biotech Executive &amp; Wall Street Analyst Brings Deep Expertise in Precision Neurooncology, Biopharma Partnering and Clinical Development </li> </ul> <p> DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence, machine learning and genomic data to transform the cost, pace and timeline of oncology drug discovery and development, today announced the appointment of Lee T. Schalop, MD, to its Board of Directors. </p><p> Dr. Schalop brings over two decades of combined experience in biotechnology leadership and financial markets, with particular expertise in precision neurooncology and clinical development. Most notably, he co-founded and was a key member of http://www.streetinsider.com/Press+Releases/Lantern+Pharma+Announces+Appointment+of+Dr.+Lee+Schalop+to+Board+of+Directors/25103014.html Mon, 28 Jul 2025 08:00:00 -0400 0N6A A.00756693 A.03607790 A.13384720 A.16949560 A.35871300 ALTME CMRX LTRN O.00159267 O.20147506 O.20831026 O.30873959 O.40825805 O.47731837 http://www.streetinsider.com/Press+Releases/Lantern+Pharma+Announces+Appointment+of+Dr.+Lee+Schalop+to+Board+of+Directors/25103014.html <ul class="bwlistsquare"> <li> Seasoned Biotech Executive &amp; Wall Street Analyst Brings Deep Expertise in Precision Neurooncology, Biopharma Partnering and Clinical Development </li> </ul> <p> DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence, machine learning and genomic data to transform the cost, pace and timeline of oncology drug discovery and development, today announced the appointment of Lee T. Schalop, MD, to its Board of Directors. </p><p> Dr. Schalop brings over two decades of combined experience in biotechnology leadership and financial markets, with particular expertise in precision neurooncology and clinical development. Most notably, he co-founded and was a key member of http://www.streetinsider.com/Press+Releases/Lantern+Pharma+Announces+Appointment+of+Dr.+Lee+Schalop+to+Board+of+Directors/25103014.html Mon, 28 Jul 2025 08:00:00 -0400 0N6A A.00756693 A.03607790 A.13384720 A.16949560 A.35871300 ALTME CMRX LTRN O.00159267 O.20147506 O.20831026 O.30873959 O.40825805 O.47731837 http://www.streetinsider.com/Press+Releases/Lantern+Pharma+Announces+Appointment+of+Dr.+Lee+Schalop+to+Board+of+Directors/25103014.html <ul class="bwlistsquare"> <li> Seasoned Biotech Executive &amp; Wall Street Analyst Brings Deep Expertise in Precision Neurooncology, Biopharma Partnering and Clinical Development </li> </ul> <p> DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence, machine learning and genomic data to transform the cost, pace and timeline of oncology drug discovery and development, today announced the appointment of Lee T. Schalop, MD, to its Board of Directors. </p><p> Dr. Schalop brings over two decades of combined experience in biotechnology leadership and financial markets, with particular expertise in precision neurooncology and clinical development. Most notably, he co-founded and was a key member of http://www.streetinsider.com/Press+Releases/Lantern+Pharma+Announces+Appointment+of+Dr.+Lee+Schalop+to+Board+of+Directors/25103014.html Mon, 28 Jul 2025 08:00:00 -0400 0N6A A.00756693 A.03607790 A.13384720 A.16949560 A.35871300 ALTME CMRX LTRN O.00159267 O.20147506 O.20831026 O.30873959 O.40825805 O.47731837 http://www.streetinsider.com/Press+Releases/Lantern+Pharma+Announces+Appointment+of+Dr.+Lee+Schalop+to+Board+of+Directors/25103014.html <ul class="bwlistsquare"> <li> Seasoned Biotech Executive &amp; Wall Street Analyst Brings Deep Expertise in Precision Neurooncology, Biopharma Partnering and Clinical Development </li> </ul> <p> DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence, machine learning and genomic data to transform the cost, pace and timeline of oncology drug discovery and development, today announced the appointment of Lee T. Schalop, MD, to its Board of Directors. </p><p> Dr. Schalop brings over two decades of combined experience in biotechnology leadership and financial markets, with particular expertise in precision neurooncology and clinical development. Most notably, he co-founded and was a key member of http://www.streetinsider.com/Press+Releases/Lantern+Pharma+Announces+Appointment+of+Dr.+Lee+Schalop+to+Board+of+Directors/25103014.html Mon, 28 Jul 2025 08:00:00 -0400 0N6A A.00756693 A.03607790 A.13384720 A.16949560 A.35871300 ALTME CMRX LTRN O.00159267 O.20147506 O.20831026 O.30873959 O.40825805 O.47731837 http://www.streetinsider.com/Press+Releases/Lantern+Pharma+Announces+Appointment+of+Dr.+Lee+Schalop+to+Board+of+Directors/25103014.html <ul class="bwlistsquare"> <li> Seasoned Biotech Executive &amp; Wall Street Analyst Brings Deep Expertise in Precision Neurooncology, Biopharma Partnering and Clinical Development </li> </ul> <p> DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence, machine learning and genomic data to transform the cost, pace and timeline of oncology drug discovery and development, today announced the appointment of Lee T. Schalop, MD, to its Board of Directors. </p><p> Dr. Schalop brings over two decades of combined experience in biotechnology leadership and financial markets, with particular expertise in precision neurooncology and clinical development. Most notably, he co-founded and was a key member of http://www.streetinsider.com/Press+Releases/Lantern+Pharma+Announces+Appointment+of+Dr.+Lee+Schalop+to+Board+of+Directors/25103014.html Mon, 28 Jul 2025 08:00:00 -0400 0N6A A.00756693 A.03607790 A.13384720 A.16949560 A.35871300 ALTME CMRX LTRN O.00159267 O.20147506 O.20831026 O.30873959 O.40825805 O.47731837 http://www.streetinsider.com/Press+Releases/Lantern+Pharma+Announces+Appointment+of+Dr.+Lee+Schalop+to+Board+of+Directors/25103014.html <ul class="bwlistsquare"> <li> Seasoned Biotech Executive &amp; Wall Street Analyst Brings Deep Expertise in Precision Neurooncology, Biopharma Partnering and Clinical Development </li> </ul> <p> DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence, machine learning and genomic data to transform the cost, pace and timeline of oncology drug discovery and development, today announced the appointment of Lee T. Schalop, MD, to its Board of Directors. </p><p> Dr. Schalop brings over two decades of combined experience in biotechnology leadership and financial markets, with particular expertise in precision neurooncology and clinical development. Most notably, he co-founded and was a key member of http://www.streetinsider.com/Press+Releases/Lantern+Pharma+Announces+Appointment+of+Dr.+Lee+Schalop+to+Board+of+Directors/25103014.html Mon, 28 Jul 2025 08:00:00 -0400 0N6A A.00756693 A.03607790 A.13384720 A.16949560 A.35871300 ALTME CMRX LTRN O.00159267 O.20147506 O.20831026 O.30873959 O.40825805 O.47731837 http://www.streetinsider.com/Press+Releases/Lantern+Pharma+Announces+Appointment+of+Dr.+Lee+Schalop+to+Board+of+Directors/25103014.html <ul class="bwlistsquare"> <li> Seasoned Biotech Executive &amp; Wall Street Analyst Brings Deep Expertise in Precision Neurooncology, Biopharma Partnering and Clinical Development </li> </ul> <p> DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence, machine learning and genomic data to transform the cost, pace and timeline of oncology drug discovery and development, today announced the appointment of Lee T. Schalop, MD, to its Board of Directors. </p><p> Dr. Schalop brings over two decades of combined experience in biotechnology leadership and financial markets, with particular expertise in precision neurooncology and clinical development. Most notably, he co-founded and was a key member of http://www.streetinsider.com/Press+Releases/Lantern+Pharma+Announces+Appointment+of+Dr.+Lee+Schalop+to+Board+of+Directors/25103014.html Mon, 28 Jul 2025 08:00:00 -0400 0N6A A.00756693 A.03607790 A.13384720 A.16949560 A.35871300 ALTME CMRX LTRN O.00159267 O.20147506 O.20831026 O.30873959 O.40825805 O.47731837 http://www.streetinsider.com/Press+Releases/Lantern+Pharma+Announces+Appointment+of+Dr.+Lee+Schalop+to+Board+of+Directors/25103014.html <ul class="bwlistsquare"> <li> Seasoned Biotech Executive &amp; Wall Street Analyst Brings Deep Expertise in Precision Neurooncology, Biopharma Partnering and Clinical Development </li> </ul> <p> DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence, machine learning and genomic data to transform the cost, pace and timeline of oncology drug discovery and development, today announced the appointment of Lee T. Schalop, MD, to its Board of Directors. </p><p> Dr. Schalop brings over two decades of combined experience in biotechnology leadership and financial markets, with particular expertise in precision neurooncology and clinical development. Most notably, he co-founded and was a key member of http://www.streetinsider.com/Press+Releases/Lantern+Pharma+Announces+Appointment+of+Dr.+Lee+Schalop+to+Board+of+Directors/25103014.html Mon, 28 Jul 2025 08:00:00 -0400 0N6A A.00756693 A.03607790 A.13384720 A.16949560 A.35871300 ALTME CMRX LTRN O.00159267 O.20147506 O.20831026 O.30873959 O.40825805 O.47731837 http://www.streetinsider.com/Press+Releases/Lantern+Pharma+Announces+Appointment+of+Dr.+Lee+Schalop+to+Board+of+Directors/25103014.html <ul class="bwlistsquare"> <li> Seasoned Biotech Executive &amp; Wall Street Analyst Brings Deep Expertise in Precision Neurooncology, Biopharma Partnering and Clinical Development </li> </ul> <p> DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence, machine learning and genomic data to transform the cost, pace and timeline of oncology drug discovery and development, today announced the appointment of Lee T. Schalop, MD, to its Board of Directors. </p><p> Dr. Schalop brings over two decades of combined experience in biotechnology leadership and financial markets, with particular expertise in precision neurooncology and clinical development. Most notably, he co-founded and was a key member of http://www.streetinsider.com/Press+Releases/Lantern+Pharma+Announces+Appointment+of+Dr.+Lee+Schalop+to+Board+of+Directors/25103014.html Mon, 28 Jul 2025 08:00:00 -0400 0N6A A.00756693 A.03607790 A.13384720 A.16949560 A.35871300 ALTME CMRX LTRN O.00159267 O.20147506 O.20831026 O.30873959 O.40825805 O.47731837 http://www.streetinsider.com/Press+Releases/Lantern+Pharma+Announces+Appointment+of+Dr.+Lee+Schalop+to+Board+of+Directors/25103014.html <ul class="bwlistsquare"> <li> Seasoned Biotech Executive &amp; Wall Street Analyst Brings Deep Expertise in Precision Neurooncology, Biopharma Partnering and Clinical Development </li> </ul> <p> DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence, machine learning and genomic data to transform the cost, pace and timeline of oncology drug discovery and development, today announced the appointment of Lee T. Schalop, MD, to its Board of Directors. </p><p> Dr. Schalop brings over two decades of combined experience in biotechnology leadership and financial markets, with particular expertise in precision neurooncology and clinical development. Most notably, he co-founded and was a key member of http://www.streetinsider.com/Press+Releases/Lantern+Pharma+Announces+Appointment+of+Dr.+Lee+Schalop+to+Board+of+Directors/25103014.html Mon, 28 Jul 2025 08:00:00 -0400 0N6A A.00756693 A.03607790 A.13384720 A.16949560 A.35871300 ALTME CMRX LTRN O.00159267 O.20147506 O.20831026 O.30873959 O.40825805 O.47731837